Advancing PrEP for HIV prevention: innovations and the imperative to preserve comprehensive care
- PMID: 39885612
- PMCID: PMC11784111
- DOI: 10.1186/s44263-025-00125-1
Advancing PrEP for HIV prevention: innovations and the imperative to preserve comprehensive care
Conflict of interest statement
Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: ABA is an editorial board member of the journal. The remaining author declares no competing interests.
References
-
- Mayer KH, Molina J, Thompson MA, et al. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. The Lancet. 2020;396(10246):239–54. - PMC - PubMed
-
- Mast J. Gilead to test once-a-year HIV prevention shot. STAT. 2024. https://www.statnews.com/2024/12/11/hiv-prevention-gilead-once-a-year-prep/.
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous